news
NICE recommends Lilly’s Olaratumab (Lartruvo) to treat sarcoma
Olaratumab is the first monoclonal antibody, in combination with doxorubicin, to be recommended for the treatment of advanced soft tissue sarcoma.
List view / Grid view
Olaratumab (Lartruvo)
news
EC approval for Lilly’s soft tissue sarcoma drug Olaratumab
18 November 2016 | By Niamh Louise Marriott, Digital Content Producer
This conditional marketing authorisation is based on data from the Phase 2 portion of the pivotal JGDG trial and followed a positive recommendation from...
news
Combining soft-tissue cancer drugs improves survival
21 July 2016 | By Niamh Louise Marriott, Digital Content Producer
Scientists discovered that adding a novel monoclonal antibody therapy to traditional chemotherapy increased survival by nearly a year in patients with advanced sarcoma, a lethal soft-tissue cancer.
news
FDA grants Priority Review for olaratumab BLA
4 May 2016 | By Victoria White, Digital Content Producer
The US Food and Drug Administration (FDA) has granted Priority Review to Lilly’s biologics license application (BLA) for olaratumab, in combination with doxorubicin, for the potential treatment of people with advanced soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery.
